Literature DB >> 6838633

Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism.

P Workman, P R Twentyman, F Y Lee, M I Walton.   

Abstract

The nitroimidazole misonidazole (MISO) and related compounds have been shown to enhance the response of tumours to cytotoxic agents, and often to improve their therapeutic indices. Previous experiments suggested inhibition of cytotoxic drug metabolism as a mechanism. We have now investigated the effects of MISO and related compounds on drug metabolism in mice, and the results can be summarised as follows. (1) MISO and related compounds inhibit drug-metabolising enzymes, as measured by pentobarbitone sleep-time and zoxazolamine paralysis-time. (2) Enzyme inhibition is primarily dependent on lipophilicity, with maximum inhibition exhibited by the most active chemosensitizers. (3) MISO significantly slowed the clearance of pentobarbitone, aminopyrine and the cytotoxic agent chlorambucil, but had no effect on renal function or protein binding. These data support the view that inhibition of cytotoxic drug metabolism may be an important factor in chemosensitization.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6838633     DOI: 10.1016/0006-2952(83)90588-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Pharmacokinetic basis for the comparative antitumour activity and toxicity of chlorambucil, phenylacetic acid mustard and beta, beta-difluorochlorambucil (CB 7103) in mice.

Authors:  F Y Lee; P Coe; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

Authors:  F Y Lee; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis.

Authors:  S N Moreno; R Docampo
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

4.  Preclinical pharmacokinetics of benznidazole.

Authors:  P Workman; R A White; M I Walton; L N Owen; P R Twentyman
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

5.  Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640

6.  Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo.

Authors:  D Murray; R E Meyn
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

7.  Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.

Authors:  M R Horsman; J W Evans; J M Brown
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

8.  Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640

9.  Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain.

Authors:  F Y Lee; P Workman
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

10.  Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.

Authors:  R E Durand; D J Chaplin
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.